Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

NCT05488548 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Castrate Resistant Prostate Cancer
NUT Carcinoma
Chronic Myelomonocytic Leukemia
Myelofibrosis

Interventions

DRUG: EP31670

Sponsor

Epigenetix, Inc.